FN
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Effect of Direct Acting Antiviral Drugs on the Occurrence and Recurrence of Intra- and Extra-Hepatic Malignancies in Patients with Chronic Hepatitis C Virus Infection | Cancers | 2024 | 7 | 12 | |||
| A global research priority agenda to advance public health responses to fatty liver disease | Journal of hepatology | 2023 | 120 | 367 | |||
| ANGPTL4 is a potential driver of HCV-induced peripheral insulin resistance | Scientific reports | 2023 | 178 | 86 | |||
| HCV disease burden and population segments in Switzerland | Liver international | 2022 | 247 | 211 | |||
| Maladies infectieuses | Revue médicale suisse | 2021 | 388 | 110 | |||
| The never-ending debate about conflict of interests' | Liver international | 2021 | 168 | 82 | |||
| NAFLD and MAFLD as emerging causes of HCC: a populational study | JHEP Reports : Innovation in hepathology | 2021 | 324 | 269 | |||
| Endpoints and New Options for Treatment of Chronic Hepatitis D | Hepatology | 2021 | 140 | 195 | |||
| Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in Switzerland | Swiss Medical Weekly | 2021 | 255 | 113 | |||
| Recommandations pour le suivi des patients atteints d'hépatite C guérie | Swiss Medical Forum | 2021 | 238 | 192 | |||
| HDV pathogenesis: unravelling ariadne's thread | Viruses | 2021 | 209 | 122 | |||
| Hepatitis C prevalence in the psychiatric setting: cost-effectiveness of scaling-up screening and direct-acting antiviral therapy | JHEP Reports : Innovation in Hepatology | 2021 | 304 | 176 | |||
| Real-world outcomes in historically underserved patients with chronic hepatitis C infection treated with Glecaprevir/Pibrentasvir | Infectious Diseases and Therapy | 2021 | 240 | 94 | |||
| Residual risk of liver disease after hepatitis C virus eradication | Journal of Hepatology | 2021 | 206 | 0 | |||
| MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective | Alimentary Pharmacology and Therapeutics | 2021 | 275 | 0 | |||
| The case for simplifying and using absolute targets for viral hepatitis elimination goals | Journal of Viral Hepatitis | 2021 | 206 | 0 | |||
| Hepatitis C core antigen test as an alternative for diagnosing HCV infection: mathematical model and cost-effectiveness analysis | PeerJ | 2021 | 374 | 133 | |||
| The changing context of hepatitis D | Journal of Hepatology | 2021 | 238 | 0 | |||
| Mir-21 Suppression Promotes Mouse Hepatocarcinogenesis | Cancers | 2021 | 256 | 422 | |||
| Hepatitis C virus: current steps toward elimination in Germany and barriers to reaching the 2030 goal | Health science reports | 2021 | 308 | 258 | |||
| EASL recommendations on treatment of hepatitis C: final update of the series | Journal of Hepatology | 2020 | 293 | 0 | |||
| Buyers' club : une alternative pour l'accès au traitement ? | Revue médicale suisse | 2020 | 413 | 234 | |||
| A letter of solidarity during the COVID-19 pandemic | Liver International | 2020 | 166 | 98 | |||
| Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic hcv infection: a meta-analysis | Journal of Hepatology | 2020 | 260 | 274 | |||
| Chronic hepatitis D and hepatocellular carcinoma: a systematic review and meta-analysis of observational studies | Journal of Hepatology | 2020 | 322 | 1 | |||
| Reply to: "Cirrhotic controls in a pooled analysis of hepatitis D and hepatocellular carcinoma" | Journal of Hepatology | 2020 | 233 | 155 | |||
| SARS-CoV-2 and liver damage: a possible pathogenetic link | Hepatobiliary Surgery and Nutrition | 2020 | 228 | 145 | |||
| Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis? | Swiss Medical Weekly | 2020 | 335 | 192 | |||
| Securing sustainable funding for viral hepatitis elimination plans | Liver International | 2020 | 358 | 0 | |||
| Natural history of NASH and HCC | Liver International | 2020 | 339 | 1 | |||
| The MD-PhD program in Geneva: a 10-year analysis of graduate demographics and outcomes | BMC Medical Education | 2020 | 300 | 337 | |||
| All-Cause mortality and causes of death in the Swiss Hepatitis C Cohort Study (SCCS) | Open Forum Infectious Diseases | 2020 | 383 | 182 | |||
| Modelling the Impact and Cost-Effectiveness of Extended Screening and Treatment with Direct-Acting Antivirals in a Swiss Custodial Setting | Clinical Infectious Diseases | 2019 | 425 | 326 | |||
| Treatment with direct-acting antivirals improves peripheral insulin sensitivity in non-diabetic, lean chronic hepatitis c patients | PLOS ONE | 2019 | 429 | 208 | |||
| Interleukin-1 receptor antagonist modulates liver inflammation and fibrosis in mice in a model-dependent manner | International Journal of Molecular Sciences | 2019 | 528 | 267 | |||
| A review on hepatitis D: from virology to new therapies | Journal of Advanced Research | 2019 | 462 | 330 | |||
| Impact of geographic origin on access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study | PLOS ONE | 2019 | 467 | 222 | |||
| Devil hepatitis D: an orphan disease or largely underdiagnosed? | Gut | 2019 | 389 | 0 | |||
| Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: a pooled analysis of clinical trials | Liver International | 2019 | 303 | 79 | |||
| Very low hepatitis C viral loads in treatment-naïve persons: do they compromise hepatitis C virus antigen testing? | Clinical Infectious Diseases | 2019 | 539 | 178 | |||
| Programme national de lutte contre le VIH, les IST et l'hépatite virale: unir les forces contre le VIH et les hépatites virales | Bulletin des médecins suisses | 2019 | 483 | 211 | |||
| Identification of an endoglin variant associated with HCV-related liver fibrosis progression by next-generation sequencing | Frontiers in Genetics | 2019 | 343 | 144 | |||
| Natural history of hepatic and extrahepatic hepatitis C virus diseases and impact of interferon-free HCV therapy | Cold Spring Harbor Perspectives in Medicine | 2019 | 311 | 2 | |||
| Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates | Clinical Gastroenterology and Hepatology | 2019 | 394 | 0 | |||
| Activation of the oncogenic miR-21-5p promotes HCV replication and steatosis induced by the viral core 3a protein | Liver International | 2019 | 459 | 317 | |||
| Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis | Journal of Viral Hepatitis | 2019 | 340 | 161 | |||
| Nonalcoholic fatty liver disease burden | Swiss Medical Weekly | 2019 | 314 | 230 | |||
| Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions | Swiss Medical Weekly | 2019 | 440 | 310 | |||
| Tolerogenic propreties of liver macrophages in non-alcoholic steatohepatitis | Liver International | 2019 | 473 | 567 | |||
| Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland | Swiss Medical Weekly | 2019 | 1,115 | 295 | |||
| Increasing hepatitis C virus screening in people who inject drugs in Switzerland using rapid antibody saliva and dried blood spot testing: A cost-effectiveness analysis | Journal of Viral Hepatitis | 2019 | 440 | 1 | |||
| The heavy burden of hepatitis D in Uzbekistan | Liver International | 2019 | 317 | 0 | |||
| Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study | The Lancet Gastroenterology & Hepatology | 2018 | 367 | 0 | |||
| Hepatitis B prevalence, risk factors, infection awareness and disease knowledge among inmates: a cross-sectional study in Switzerland's largest pre-trial prison | Journal of Global Health | 2018 | 427 | 260 | |||
| Current and Future Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH) | Hepatology | 2018 | 486 | 835 | |||
| Collagen proportionate area correlates to hepatic venous pressure gradient in non-abstinent cirrhotic patients with alcoholic liver disease | World Journal of Hepatology | 2018 | 442 | 310 | |||
| Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030 | Journal of Hepatology | 2018 | 1,143 | 784 | |||
| Deficient natural killer cell NKp30-mediated function and altered NCR3 splice variants in hepatocellular carcinoma | Hepatology | 2018 | 506 | 0 | |||
| Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries | Antiviral Research | 2018 | 436 | 0 | |||
| A buyers' club to improve access to hepatitis C treatment for vulnerable populations | Swiss Medical Weekly | 2018 | 1,236 | 483 | |||
| EASL Clinical Practice Guidelines on hepatitis E virus infection | Journal of Hepatology | 2018 | 501 | 2 | |||
| The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic disease | Journal of Viral Hepatitis | 2018 | 327 | 211 | |||
| Coinfections between Persistent Parasitic Neglected Tropical Diseases and Viral Infections among Prisoners from Sub-Saharan Africa and Latin America | Journal of Tropical Medicine | 2018 | 749 | 332 | |||
| Expert opinion on the management of renal manifestations of chronic HCV infection | Antiviral Therapy | 2018 | 359 | 0 | |||
| EASL Recommendations on Treatment of Hepatitis C 2018 | Journal of Hepatology | 2018 | 372 | 0 | |||
| Combler les lacunes dans les tests de dépistage de l'hépatite | Bulletin des médecins suisses | 2018 | 473 | 197 | |||
| Expanded benefits of curing the extrahepatic manifestations of HCV infection | Gut | 2018 | 312 | 263 | |||
| Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis | Hepatology | 2018 | 316 | 0 | |||
| Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies | Journal of Hepatology | 2018 | 495 | 1 | |||
| Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030? | PLOS ONE | 2018 | 426 | 210 | |||
| Effect of hepatitis B virus on steatosis in hepatitis C virus co-infected subjects: A multi-centre study and systematic review | Journal of Viral Hepatitis | 2018 | 531 | 0 | |||
| Cardiovascular Manifestations of Hepatitis C Virus | Clinics in Liver Disease | 2017 | 490 | 2 | |||
| Hépatite B : nouvelles recommandations de prise en charge | Revue médicale suisse | 2017 | 582 | 2 | |||
| Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study | The Lancet Gastroenterology & Hepatology | 2017 | 327 | 0 | |||
| Current level of evidence on causal association between hepatitis C virus and type 2 diabetes: A review | Journal of Advanced Research | 2017 | 517 | 416 | |||
| Access to hepatitis C treatment for patients in drug substitution programmes: the fight is far from over | Swiss Medical Weekly | 2017 | 427 | 196 | |||
| Estimating HCV disease burden-volume 4 (editorial) | Journal of Viral Hepatitis | 2017 | 388 | 0 | |||
| Extrahepatic manifestations in hepatitis C virus infection | Journal of Advanced Research | 2017 | 428 | 151 | |||
| Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030 | Swiss Medical Weekly | 2017 | 939 | 237 | |||
| Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study | The Lancet Gastroenterology & Hepatology | 2017 | 356 | 0 | |||
| Hepatic protein tyrosine phosphatase receptor gamma links obesity-induced inflammation to insulin resistance | Nature Communications | 2017 | 1,556 | 434 | |||
| The impact of hepatitis C virus outside the liver: Evidence from Asia | Liver international | 2017 | 433 | 1 | |||
| Editor's note | Liver International | 2017 | 274 | 0 | |||
| Hépatites B et C : nouveaux traitements | Revue médicale suisse | 2017 | 403 | 0 | |||
| Health-related quality of life in chronic HCV-infected patients switching to pegylated-interferon-free regimens (ARNS CO20 CUPIC cohort study and SIRIUS trial) | The Patient - Patient-Centered Outcomes Research | 2017 | 287 | 1 | |||
| A Systematic Review and Meta-Analysis of HCV Clearance | Liver international | 2017 | 603 | 1 | |||
| Nucleic acid polymers: much-needed hope for hepatitis D? | The Lancet Gastroenterology & Hepatology | 2017 | 391 | 1 | |||
| BRIP1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease | Oncotarget | 2017 | 567 | 2 | |||
| Trends in hepatitis C-related mortality in Switzerland | Journal of Hepatology | 2017 | 1,253 | 809 | |||
| The negative impact of HBV/HCV coinfection on cirrhosis and its consequences | Alimentary Pharmacology and Therapeutics | 2017 | 475 | 0 | |||
| Hepatitis C Virus Increases Occludin Expression via the Upregulation of Adipose Differentiation-Related Protein | PloS one | 2016 | 1,164 | 244 | |||
| Effect of quercetin on hepatitis C virus life cycle: from viral to host targets | Scientific Reports | 2016 | 476 | 181 | |||
| Ribavirin restores IFNα responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes | Gut | 2016 | 369 | 1 | |||
| Quels espoirs pour l'hépatite delta ? | Revue médicale suisse | 2016 | 436 | 1 | |||
| Characteristics of Foreign-Born Persons in the Swiss Hepatitis C Cohort Study: Implications for Screening Recommendations | PloS one | 2016 | 633 | 565 | |||
| Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin | Journal of hepatology | 2016 | 522 | 3 | |||
| The hepatitis delta virus: Replication and pathogenesis | Journal of hepatology | 2016 | 564 | 2 | |||
| Phosphatase and tensin homolog is a differential diagnostic marker between nonalcoholic and alcoholic fatty liver disease | World journal of gastroenterology | 2016 | 607 | 6 | |||
| Nonalcoholic Steatohepatitis Is Associated With Increased Mortality in Obese Patients Undergoing Bariatric Surgery | Clinical gastroenterology and hepatology | 2016 | 543 | 0 | |||
| A significant effect of the killer cell immunoglobulin-like receptor ligand human leucocyte antigen-C on fibrosis progression in chronic C hepatitis with or without liver transplantation | Liver international | 2016 | 563 | 1 | |||
| Drug Pricing Evolution in Hepatitis C | PloS one | 2016 | 1,367 | 636 | |||
| Corrigendum: reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes | Nature communications | 2015 | 579 | 166 | |||
| ABO incompatible kidney transplantation from an anti-hepatitis C virus antibody-positive RNA-negative donor into an anti-hepatitis C virus antibody-negative recipient | Transplant international | 2015 | 659 | 1 | |||
| Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland | PloS one | 2015 | 618 | 1,375 | |||
| Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland | Schweizerische medizinische Wochenschrift | 2015 | 612 | 249 | |||
| The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients | Journal of Viral Hepatitis | 2015 | 318 | 0 | |||
| Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C | PloS one | 2015 | 728 | 387 | |||
| A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance | Hepatology | 2015 | 374 | 0 | |||
| Are statins a remedy for all seasons? | Journal of hepatology | 2015 | 621 | 259 | |||
| Extrahepatic morbidity and mortality of chronic hepatitis C | Gastroenterology | 2015 | 493 | 0 | |||
| The evolutionary patterns of hepatitis C virus subtype 2a and 6a isolates linked to an outbreak in China in 2012 | Virology | 2015 | 530 | 0 | |||
| Impact of IL28B, APOH and ITPA polymorphisms on efficacy and safety of TVR- or BOC-based triple therapy in treatment-experienced HCV-1 patients with compensated cirrhosis from the ANRS CO20_CUPIC study | PLOS ONE | 2015 | 303 | 233 | |||
| Repenser la politique de remboursement des agents antiviraux directs contre l'hépatite C chronique | Revue médicale suisse | 2015 | 547 | 1 | |||
| Extrahepatic manifestations of HCV | Minerva gastroenterologica e dietologica | 2015 | 552 | 0 | |||
| The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection | Alimentary pharmacology & therapeutics | 2014 | 637 | 0 | |||
| Is genotype 3 of the hepatitis C virus the new villain ? | Hepatology | 2014 | 345 | 0 | |||
| Clinical significance of the CCR5delta32 allele in hepatitis C | PloS one | 2014 | 586 | 255 | |||
| HCV 3a core protein increases lipid droplet cholesteryl ester content via a mechanism dependent on sphingolipid biosynthesis | PloS one | 2014 | 603 | 266 | |||
| Curbing hepatitis C virus spread in Egypt | The Lancet. Global health | 2014 | 564 | 0 | |||
| Historical epidemiology of hepatitis C virus (HCV) in selected countries | Journal of viral hepatitis | 2014 | 627 | 1 | |||
| Hepatitis D virus coinfection and superinfection | Cold Spring Harbor perspectives in medicine | 2014 | 523 | 0 | |||
| The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm | Journal of viral hepatitis | 2014 | 596 | 1 | |||
| The impact of obesity and metabolic syndrome on chronic hepatitis C | Clinics in liver disease | 2014 | 570 | 0 | |||
| Origin of hepatitis C virus genotype 3 in Africa as estimated through an evolutionary analysis of the full-length genomes of nine subtypes, including the newly sequenced 3d and 3e | Journal of general virology | 2014 | 544 | 0 | |||
| EASL Clinical Practice Guidelines: management of hepatitis C virus infection | Journal of hepatology | 2014 | 610 | 0 | |||
| Transplantation cellulaire : traitements actuels et perspectives d'avenir | Revue médicale suisse | 2014 | 926 | 14 | |||
| Does telaprevir possess a direct antidiabetic effect? | Liver international | 2014 | 619 | 0 | |||
| Novel Approach Identifies SNPs in SLC2A10 and KCNK9 with Evidence for Parent-of-Origin Effect on Body Mass Index | PLOS genetics | 2014 | 752 | 1,281 | |||
| Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases | Journal of hepatology | 2014 | 580 | 303 | |||
| Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon-α and ribavirin in chronic hepatitis C virus patients | Liver international | 2014 | 608 | 0 | |||
| Epidemiology of hepatitis C in Europe | Digestive and Liver Disease | 2014 | 584 | 289 | |||
| Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes | Nature communications | 2014 | 677 | 1,244 | |||
| Insulin resistance, non-alcoholic fatty liver disease and hepatitis C virus infection | Reviews on recent clinical trials | 2014 | 563 | 0 | |||
| Strategies to manage hepatitis C virus (HCV) disease burden | Journal of viral hepatitis | 2014 | 601 | 1 | |||
| Hepatitis C in 2013: HCV causes systemic disorders that can be cured | Nature reviews. Gastroenterology & hepatology | 2014 | 614 | 2 | |||
| Morbidité et mortalité extrahépatiques associées à l'infection par le virus de l'hépatite C | Revue médicale suisse | 2014 | 554 | 1 | |||
| Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma development | PloS one | 2013 | 705 | 644 | |||
| PTEN protein phosphatase activity regulates hepatitis C virus secretion through modulation of cholesterol metabolism | Journal of hepatology | 2013 | 704 | 2 | |||
| Comparative genetic analyses point to HCP5 as susceptibility locus for HCV-associated hepatocellular carcinoma | Journal of hepatology | 2013 | 670 | 0 | |||
| Role of seipin in lipid droplet morphology and hepatitis C virus life cycle | Journal of general virology | 2013 | 656 | 1 | |||
| IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction | The Journal of experimental medicine | 2013 | 570 | 0 | |||
| Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection | PloS one | 2013 | 641 | 228 | |||
| STAT6 promotes bi-directional modulation of PKM2 in liver and adipose inflammatory cells in Rosiglitazone-treated mice | Scientific reports | 2013 | 707 | 3 | |||
| Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial | Hepatology | 2013 | 596 | 0 | |||
| Intrahepatic mRNA levels of SOCS1 and SOCS3 are associated with cirrhosis but do not predict virological response to therapy in chronic hepatitis C | Liver international | 2013 | 667 | 0 | |||
| Réactivation de l'hépatite B au cours de l'immunosuppression | Revue médicale suisse | 2013 | 587 | 0 | |||
| Hepatitis B and C in Switzerland - healthcare provider initiated testing for chronic hepatitis B and C infection | Schweizerische medizinische Wochenschrift | 2013 | 676 | 0 | |||
| Statins may protect against hepatocellular carcinoma development in patients infected with hepatitis C virus, but what are the mechanisms? | Journal of clinical oncology | 2013 | 616 | 0 | |||
| IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4 | Journal of viral hepatitis | 2013 | 641 | 0 | |||
| IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5 | Gut | 2012 | 592 | 0 | |||
| Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy | Hepatology | 2012 | 642 | 0 | |||
| HCV infection and metabolic syndrome: which is the chicken and which is the egg? | Gastroenterology | 2012 | 451 | 0 | |||
| The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated-interferon/ribavirin-based therapy in chronic hepatitis C patients | Antiviral therapy | 2012 | 679 | 1 | |||
| Steatosis and insulin resistance in response to treatment of chronic hepatitis C | Journal of viral hepatitis | 2012 | 605 | 0 | |||
| Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II study | Hepatology | 2012 | 621 | 0 | |||
| A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C | PloS one | 2012 | 766 | 406 | |||
| Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C | Journal of viral hepatitis | 2012 | 667 | 0 | |||
| Nonalcoholic fatty liver disease in lean individuals in the United States | Medicine | 2012 | 571 | 0 | |||
| IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes | Hepatology | 2012 | 657 | 0 | |||
| Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection | Gastroenterology | 2012 | 630 | 0 | |||
| The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirin | Journal of viral hepatitis | 2012 | 630 | 0 | |||
| The interaction of metabolic factors with HCV infection: does it matter? | Journal of hepatology | 2012 | 598 | 0 | |||
| Post-load insulin resistance does not predict virological response to treatment of chronic hepatitis C patients without the metabolic syndrome | Digestive and Liver Disease | 2012 | 563 | 0 | |||
| Défis de la co-infection par le virus de l'hépatite C et le VIH | Revue médicale suisse | 2012 | 622 | 0 | |||
| Liver kidney microsomal type 1 antibodies reduce the CYP2D6 activity in patients with chronic hepatitis C virus infection | Journal of viral hepatitis | 2012 | 663 | 0 | |||
| Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma | Schweizerische medizinische Wochenschrift | 2012 | 561 | 0 | |||
| Deficiency in the NADPH oxidase 4 predisposes towards diet-induced obesity | International journal of obesity | 2012 | 769 | 5 | |||
| Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study | BMC gastroenterology | 2012 | 641 | 185 | |||
| The global health burden of hepatitis C virus infection | Liver international | 2011 | 565 | 0 | |||
| IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C | Journal of hepatology | 2011 | 612 | 0 | |||
| Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data | Liver international | 2011 | 634 | 0 | |||
| Trends and projections of hepatitis C virus epidemiology in Latin America | Liver international | 2011 | 656 | 0 | |||
| Mechanisms of hepatitis C virus-related insulin resistance | Clinics and research in hepatology and gastroenterology | 2011 | 558 | 0 | |||
| IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C | Alimentary Pharmacology and Therapeutics | 2011 | 191 | 0 | |||
| Effects of hepatitis C virus on suppressor of cytokine signaling mRNA levels: comparison between different genotypes and core protein sequence analysis | Journal of medical virology | 2011 | 717 | 0 | |||
| Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosis | Journal of hepatology | 2011 | 609 | 1 | |||
| Down-regulation of phosphatase and tensin homolog by hepatitis C virus core 3a in hepatocytes triggers the formation of large lipid droplets | Hepatology | 2011 | 607 | 0 | |||
| Role of hepatitis C virus genotype 3 in liver fibrosis progression--a systematic review and meta-analysis | Journal of viral hepatitis | 2011 | 572 | 0 | |||
| Enhanced B-cell differentiation and reduced proliferative capacity in chronic hepatitis C and chronic hepatitis B virus infections | Journal of hepatology | 2011 | 663 | 0 | |||
| Management of hepatitis C virus (HCV) infection in drug substitution programs | Schweizerische medizinische Wochenschrift | 2011 | 656 | 501 | |||
| A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt | Liver international | 2011 | 1,132 | 0 | |||
| Management of chronic hepatitis B: an update | Schweizerische medizinische Wochenschrift | 2011 | 579 | 0 | |||
| Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms | PloS one | 2011 | 636 | 313 | |||
| IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study | PLoS medicine | 2011 | 669 | 265 | |||
| Hépatite C chronique : traitement actuel et perspectives | Revue médicale suisse | 2011 | 506 | 1 | |||
| Nouveaux traitements de l'hépatite C : quelles cibles, quel calendrier? | Revue médicale suisse | 2011 | 529 | 0 | |||
| Hepatitis D virus: an update | Liver international | 2011 | 638 | 0 | |||
| The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients | Liver international | 2011 | 648 | 0 | |||
| A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel | Liver international | 2011 | 646 | 0 | |||
| High-density EMG E-textile systems for the control of active prostheses | Conference proceedings | 2010 | 605 | 0 | |||
| Effect of antiviral therapy on circulating cytokeratin-18 fragments in patients with chronic hepatitis C | Journal of viral hepatitis | 2010 | 584 | 1 | |||
| Impact of international consensus guidelines on antiviral therapy of chronic hepatitis C patients in Switzerland | Schweizerische medizinische Wochenschrift | 2010 | 632 | 143 | |||
| Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C | Hepatology | 2010 | 557 | 0 | |||
| Multimodal BCI-mediated FES suppression of pathological tremor | Conference proceedings | 2010 | 672 | 0 | |||
| Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection | Clinical gastroenterology and hepatology | 2010 | 568 | 0 | |||
| The hepatitis C virus core protein indirectly induces alpha-smooth muscle actin expression in hepatic stellate cells via interleukin-8 | Journal of hepatology | 2010 | 725 | 2 | |||
| Abnormalities of lipid metabolism in hepatitis C virus infection | Gut | 2010 | 563 | 0 | |||
| Cause-effect relationship between the hepatitis C virus and insulin resistance at the time of direct antiviral therapy | Gut | 2010 | 512 | 0 | |||
| Hepatitis C virus-induced steatosis: an overview | Digestive diseases | 2010 | 594 | 0 | |||
| The new EASL guidelines for the management of chronic hepatitis B infection adapted for Swiss physicians | Schweizerische medizinische Wochenschrift | 2010 | 555 | 0 | |||
| Hepatitis E virus: a zoonosis adapting to humans | The journal of antimicrobial chemotherapy | 2010 | 552 | 1 | |||
| Hépatite D:oubliée mais pas disparue | Revue médicale suisse | 2010 | 538 | 0 | |||
| Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study | Schweizerische medizinische Wochenschrift | 2010 | 706 | 0 | |||
| Experimental analysis of accuracy in the identification of motor unit spike trains from high-density surface EMG | IEEE transactions on neural systems and rehabilitation engineering | 2010 | 662 | 0 | |||
| Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study | Gastroenterology | 2010 | 894 | 0 | |||
| Adverse effects of drugs in the treatment of viral hepatitis | Baillière's best practice & research. Clinical gastroenterology | 2010 | 552 | 0 | |||
| Hepatitis delta virus inhibits alpha interferon signaling | Hepatology | 2009 | 583 | 0 | |||
| Hepatitis C virus and type 2 diabetes | World journal of gastroenterology | 2009 | 556 | 0 | |||
| Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data | Liver international | 2009 | 599 | 0 | |||
| Hepatitis C virus infection: molecular pathways to steatosis, insulin resistance and oxidative stress | Viruses | 2009 | 584 | 250 | |||
| Little evidence that hepatitis C virus leads to a higher risk of mortality in the absence of cirrhosis and excess alcohol intake: the Swiss Hepatitis C Cohort Study | Journal of viral hepatitis | 2009 | 551 | 0 | |||
| Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C | Journal of hepatology | 2009 | 651 | 0 | |||
| Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C | Journal of Viral Hepatitis | 2009 | 185 | 0 | |||
| Peroxisome proliferator-activated receptors and hepatitis C virus-induced insulin resistance | PPAR research | 2009 | 590 | 0 | |||
| Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation | Transplant infectious disease | 2009 | 527 | 0 | |||
| Chronic hepatitis E in the immunosuppressed: a new source of trouble? | Journal of hepatology | 2009 | 582 | 0 | |||
| Gene expression profile of Huh-7 cells expressing hepatitis C virus genotype 1b or 3a core proteins | Liver international | 2009 | 652 | 0 | |||
| Correction of insulin resistance in chronic hepatitis C patients not responding to the standard of care: more questions than answers | Journal of hepatology | 2009 | 553 | 0 | |||
| Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3 | Journal of hepatology | 2008 | 630 | 0 | |||
| Hepatitis C virus and glucose and lipid metabolism | Diabetes & metabolism | 2008 | 612 | 0 | |||
| Virus-induced over-expression of protein phosphatase 2A inhibits insulin signalling in chronic hepatitis C | Journal of hepatology | 2008 | 634 | 0 | |||
| Monocyte chemoattractant protein-1 secreted by adipose tissue induces direct lipid accumulation in hepatocytes | Hepatology | 2008 | 679 | 0 | |||
| Connective tissue growth factor, steatosis and fibrosis in patients with chronic hepatitis C | Liver international | 2008 | 578 | 0 | |||
| Host- rather than virus-related factors reduce health-related quality of life in hepatitis C virus infection | Gut | 2008 | 552 | 0 | |||
| Steatosis in chronic hepatitis C: friend or foe? | Liver international | 2008 | 547 | 0 | |||
| Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients | Journal of viral hepatitis | 2008 | 651 | 0 | |||
| Hepatitis C viral kinetics in plasma and peripheral blood mononuclear cells during pegylated interferon-alpha2a/ribavirin therapy | Journal of hepatology | 2008 | 626 | 0 | |||
| Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin | Journal of hepatology | 2008 | 622 | 0 | |||
| The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms | Hepatology | 2007 | 479 | 0 | |||
| Hepatitis C virus: the viral way to fatty liver | Journal of Hepatology | 2007 | 165 | 0 | |||
| Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation | Transplant international | 2004 | 809 | 0 | |||
| Hepatocellular adenoma and polycystic ovary syndrome | Liver international | 2003 | 648 | 0 | |||
| Lack of evidence for ribavirin-induced bone loss | Hepatology | 2002 | 617 | 0 | |||
| Immunological and virological effects of ribavirin in hepatitis C after liver transplantation | Transplantation | 2002 | 607 | 0 | |||
| The intrahepatic T helper cytokine profile does not predict the response to alpha-interferon in chronic hepatitis C | Journal of hepatology | 2001 | 555 | 0 | |||
| Are there any subgenomic forms of hepatitis C virus RNA in the liver? | Digestive and Liver Disease | 2001 | 610 | 0 | |||
| Expression of liver steatosis in hepatitis C virus infection and pattern of response to alpha-interferon | Journal of hepatology | 2001 | 556 | 0 | |||
| Detection of the negative-strand hepatitis C virus RNA in tissues: implications for pathogenesis | Antiviral research | 2001 | 570 | 0 | |||
| Nosocomial outbreak of multiple bloodborne viral infections | The Journal of infectious diseases | 2001 | 705 | 269 | |||
| A novel hepatitis C virus (HCV) subtype from Somalia and its classification into HCV clade 3 | Journal of general virology | 2000 | 662 | 0 | |||
| Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3 | Journal of hepatology | 2000 | 700 | 1 | |||
| Hepatitis C virus, the E2 envelope protein, and alpha-interferon resistance | Science | 2000 | 613 | 0 | |||
| Primary hepatic diffuse large B-cell lymphoma in a patient with chronic hepatitis C | The American journal of surgical pathology | 1999 | 629 | 0 | |||
| Detection of intrahepatic hepatitis C virus replication by strand-specific semi-quantitative RT-PCR: preliminary application to the liver transplantation model | Journal of hepatology | 1998 | 552 | 0 | |||
| Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV | The Journal of infectious diseases | 1998 | 618 | 0 | |||
| Hepatitis G virus infection among liver graft recipients: anatomoclinical correlations | Digestive diseases and sciences | 1998 | 605 | 0 | |||
| IgM anti-hepatitis C virus core antibodies as marker of recurrent hepatitis C after liver transplantation | Journal of medical virology | 1998 | 832 | 0 |
